Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care

Non-Small Cell Lung Carcinoma (NSCLC) Clinical Trial

Official title:

Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02558998
• Other study ID #: UPCC 34514
• Status: Completed
• Phase: N/A
• Start date: March 2015
• Est. completion date: March 2019

Study information

• Verified date: February 2020
• Source: Abramson Cancer Center of the University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to 1) evaluate the impact of a novel individualized care planning/ educational technology (the On Q Care Planning System or CPS) on oncology patient and provider knowledge, attitudes and beliefs about Non-Small Cell Lung Carcinoma (NSCLC) clinical trials, as well as 2) to evaluate the impact of the On Q CPS on patient referral to and enrollment in NSCLC clinical trials.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: March 2019
• Est. primary completion date: March 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All participants must be 18 years of age or older.

• Patient participants must have Stage III, IV and/or recurrent NSCLC.

• Patient participants must be at a point of treatment initiation/change or evaluation for treatment initiation/change

• Patients must have working email address and internet access

Exclusion Criteria:

• Any participant who cannot understand written or spoken English.

• Any participant who is not competent to provide informed consent for study participation per the investigator.

• Any participant who cannot be present for the related study visits and/or complete the post-test assessment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non-Small Cell Lung Carcinoma (NSCLC)

Intervention

Other:
• Survey

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center of the University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patient who completed surveys		8 months